Laurus Labs shares rally over 5% as promoters rule out further stake sale

Laurus Labs shares rebounded after promoter Satyanarayana Chava ruled out further stake sales, easing concerns following a sharp sell-off. Reassurances on debt-funded personal transactions, ambitious capex plans and CDMO growth also supported inve...

Agencies

Promoter reassurance lifts Laurus Labs after a 9% sell-off.

Shares of Laurus Labs rallied over 5% on Tuesday, November 17, after the pharmaceutical company's promoters reassured investors that they had no plans to sell any further stake in the company.

The clarification eased investor concerns after Monday’s 9% sell-off triggered by the sale of nearly 20 lakh shares by promoter Satyanarayana Chava and other members linked to the promoter group on November 11.

Following the latest development, Laurus Labs shares surged as much as 5.17% to hit an intraday high of Rs 2,334.90 on the NSE. The stock subsequently pared some of its gains but continued to attract strong buying interest.


Why are Laurus Labs shares rising?

The key trigger for the stock's recovery was the management's reassurance that promoters do not intend to undertake any further stake reduction in the company. Promoter Satyanarayana Chava clarified that the recent share sale was undertaken to settle personal debt and fund charitable activities, rather than due to any concerns about Laurus Labs' business prospects, according to CNBC-TV18.

He also sought to address investor concerns around the company's ambitious capital expenditure plans, which include investments of Rs 2,000 crore in FY27 and over Rs 3,000 crore in FY28.
ADVERTISEMENT

Chava indicated that the planned investments would be funded entirely through internal accruals, without creating additional financial stress, while maintaining the company's profit margins.

The promoter also highlighted Laurus Labs' transition towards becoming a fully integrated contract development and manufacturing organisation (CDMO), covering the entire spectrum from drug development to manufacturing.

He added that the transition was not expected to result in any dilution of return ratios going forward.

ALSO READ: FIIs are back with a record $11 billion. Jefferies names 10 largecap stocks to watch
ADVERTISEMENT

Laurus Labs Q2 results

Laurus Labs reported a strong financial performance in the second quarter of FY27, with revenue and profitability registering substantial year-on-year growth.
ADVERTISEMENT

The company's revenue increased to Rs 2,206 crore in Q2 FY27, compared with Rs 1,653 crore in the corresponding quarter of the previous financial year.

Net profit surged 126% year-on-year to Rs 441 crore from Rs 195 crore in Q2 FY26. EBITDA rose 78% to Rs 762 crore, compared with Rs 429 crore in the year-ago period.

EBITDA margin stood at 34.5% during the quarter, while gross margins expanded to 63% from 59.9% in Q2 FY26.

Commenting on the performance, Dr Satyanarayana Chava, Founder and Chief Executive Officer of Laurus Labs, said the company delivered another record quarter in terms of revenue and profitability, reflecting the strength of its CDMO platform and Affordable Medicines portfolio.

He highlighted the operationalisation of the company's first commercial-scale peptide manufacturing plant in Vizag, adding that a significant capacity expansion was already underway to cater to rising demand for peptide therapeutics.

The company has also announced targeted investments in oligonucleotides and peptide-resin technologies to further strengthen its integrated CDMO capabilities.

Should you buy Laurus Labs shares?

Brokerage firm Choice Institutional Equities has an 'ADD' rating on Laurus Labs, citing the company's improving business mix and its continued transition from an active pharmaceutical ingredient (API)-led business towards a CDMO-focused platform.

The brokerage expects CDMO, comprising Synthesis and Bio, to emerge as the key growth driver, with its contribution to overall revenue projected to increase to 50% by FY29E from 30% in FY26.

Key growth drivers include late-stage programmes with global partners, approximately 125 active projects and the commercialisation of peptide capabilities.

Choice Institutional Equities believes the improving business mix, coupled with operating leverage, should support margin expansion. The brokerage projects EBITDA margins of around 30% in FY27E, representing a 300-basis-point year-on-year improvement.

"Considering the stronger margin trajectory in recent quarters, we raise our FY27E/FY28E estimate by 19.9%/21.3%, respectively. We revise our target price to Rs 2,500 and retain our 'ADD' rating, implying a PEG ratio of 1.4x," the brokerage said.


Disclosure: This article has been written by Kumar Gaurav, who is not a Sebi-registered Research Analyst or an Investment Adviser. Gaurav and their ‘relative(s)’ (as defined under Section 2(77) of the Companies Act, 2013) do not hold any financial interest in the companies mentioned in this article as of the date of publication. The views/recommendations mentioned in this article, wherever applicable, are those of the respective Sebi-registered Research Analyst/brokerage and have been reproduced/reported with due attribution. They should not be construed as the views or recommendations of The Economic Times Digital or the journalist. Readers are advised to consider the original research report and make their investment decisions based on their own assessment. Brokerage disclaimers here
ADVERTISEMENT
READ MORE

READ MORE:

LOGIN & CLAIM

50 TIMESPOINTS

More from our Partners

Loading next story
Business News › Markets › Stocks › News › Laurus Labs shares rally over 5% as promoters rule out further stake sale
Text Size:AAA
Success
This article has been saved

*

+